T2 Biosystems, Inc. (TTOO) News
Filter TTOO News Items
TTOO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TTOO News Highlights
- TTOO's 30 day story count now stands at 2.
- Over the past 26 days, the trend for TTOO's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest TTOO News From Around the Web
Below are the latest news stories about T2 BIOSYSTEMS INC that investors may wish to consider to help them evaluate TTOO as an investment opportunity.
T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2022 Financial ResultsAchieved record sepsis product revenue and sepsis-driven T2Dx Instrument units in 2022LEXINGTON, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financial and operational results for the fourth quarter and full year 2022. Full Year 2022 and Recent Highlights (unaudited) Achieved full year 2022 total revenue of $22.3 million, including prod |
T2 Biosystems Announces Extension of Multiyear Innovative Technology Contract with Vizient, Inc.LEXINGTON, Mass., Dec. 28, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that its Innovative Technology contract with Vizient, Inc., the largest member-driven health care performance improvement company in the country, has been extended through March 31, 2024. The products covered under the contract with Vizient include the T2Dx® Instrument, the T2Bacteria® Panel and the T2C |
T2 Biosystems Highlights Peer-Reviewed Article Linking COVID-19 and Sepsis and Underscoring CDC Call for Adoption of Early and Accurate Microbial Diagnosis to Guide Targeted Initial Antimicrobial TherapyLEXINGTON, Mass., Dec. 08, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the publication of a peer-reviewed article published by Oxford University Press on behalf of the Infectious Diseases Society of America. "We are grateful to these distinguished authors for reinforcing the CDC’s call for adoption and implementation of early and accurate microbial diagnosis to guide target |
T2 Biosystems Third Quarter 2022 Earnings: Misses ExpectationsT2 Biosystems ( NASDAQ:TTOO ) Third Quarter 2022 Results Key Financial Results Revenue: US$3.68m (down 51% from 3Q... |
T2 Biosystems Announces Third Quarter 2022 Financial ResultsAchieves record quarterly sepsis and related revenue and advances product pipelineLEXINGTON, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced financial results for the third quarter ended September 30, 2022. Recent Commercial and Financial Highlights Achieved third quarter total revenue of $3.7 million, including product revenue of $2.6 million.A |
T2 Biosystems Announces Amendment and Extension of CRG Term Loan AgreementLEXINGTON, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the successful amendment and extension to its Term Loan Agreement with CRG Servicing LLC (“CRG”). The amendment extends both the interest-only period and the maturity date by one year from December 30, 2023 to December 30, 2024. No other material amendments were made to the Term Loan Agreement. “We conti |
T2 Biosystems to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services ForumLEXINGTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York, New York. Management is scheduled to present on Thursday, November 17, 2022, at 2pm ET. Interested parties may access a live and recorded webcast of the presentation on the “Inves |
HHS and the Cohen Foundation Name T2 Biosystems a Phase 1 Winner in LymeX Diagnostics PrizeLEXINGTON, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that the U.S. Department of Health and Human Services (“HHS”) and the Steven & Alexandra Cohen Foundation (“Cohen Foundation”) have selected T2 Biosystems as a Phase 1 winner in the LymeX Diagnostics Prize, a LymeX Innovation Accelerator (“LymeX”) prize competition to accelerate the development of Lyme d |
T2 Biosystems Regains Compliance with Nasdaq’s Minimum Bid Price RuleLEXINGTON, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it received written notice from the NASDAQ Stock Market LLC (NASDAQ) on October 31, 2022 informing the Company that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on the NASDAQ Capital Market. As previousl |
T2 Biosystems to Report Third Quarter 2022 Financial Results on November 10, 2022LEXINGTON, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the third quarter 2022 after market close on Thursday, November 10, 2022. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and |